Terms: = Lung cancer AND TRIM24, O15164, 8805, ENSG00000122779, TIF1ALPHA, TF1A, TIF1A, hTIF1, Tif1a, TIF1, RNF82, PTC6 AND Diagnosis
7 results:
1. Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis.
Fornaro M; Girolamo F; Giannini M; Coladonato L; Capuano A; Capodiferro M; D'Abbicco D; Ruggieri M; Mastrapasqua M; Iannone F
Clin Exp Rheumatol; 2024 Feb; 42(2):288-294. PubMed ID: 38488091
[TBL] [Abstract] [Full Text] [Related]
2. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
[TBL] [Abstract] [Full Text] [Related]
3. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract] [Full Text] [Related]
4. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract] [Full Text] [Related]
5. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract] [Full Text] [Related]
6. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.
Gono T; Kuwana M
Expert Rev Clin Immunol; 2020 Jan; 16(1):79-89. PubMed ID: 31779485
[No Abstract] [Full Text] [Related]
7. trim24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract] [Full Text] [Related]
